American genetic medicines company at Cambridge in Massachusetts, founded in 2016 and listed in New York. Develops non-viral genetic medicines built on its closed ended DNA platform, which is designed to give durable gene expression that can be redosed, together with cell targeted lipid nanoparticle delivery to the liver and to immune cells, aimed at both rare and common diseases, with its own research, process development and analytical laboratories.
Aucun commentaire disponible.
Laissez votre note & commentaire